# ORIGINAL RESEARCH **Biological Functions of Selenoprotein Glutathione** Peroxidases (GPXs) and their Expression in Osteoarthritis

Qianqian Zhao<sup>1,\*</sup>, Yongliang Tang<sup>2,\*</sup>, Luyu Zhang<sup>1</sup>, Na Sun<sup>3</sup>, Qiling Liu<sup>3</sup>, Rongqiang Zhang<sup>3</sup>

School of Nursing, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, People's Republic of China; <sup>2</sup>The Second Department of Orthopedics, Xi'an Central Hospital, Xi'an, Shaanxi, People's Republic of China; <sup>3</sup>School of Public Health, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, People's Republic of China

\*These authors contributed equally to this work

Correspondence: Rongqiang Zhang, School of Public Health, Shaanxi University of Chinese Medicine, No. 1 Middle Section of Century Avenue, Xianyang, Shaanxi, 712046, People's Republic of China, Tel/Fax +86-029-38185219, Email zhangroxianyang@163.com

Purpose: In order to further study the biological functions of glutathione peroxidases (GPXs) and their expression level in patients with osteoarthritis (OA), we fully explored the potential relationship between GPXs and OA. This will provide new ideas for basic biological studies and therapeutic strategies for OA patients.

Patients and Methods: In this study, bioinformatics techniques were used to explore the biological functions of five GPXs. The core genes related to the biological functions of GPXs were identified by constructing a protein-protein interaction network (PPI). In addition, we utilized microarray data in public databases to analyze the expression levels of GPXs in OA patients and healthy controls. Finally, we used quantitative real-time polymerase chain reaction (qRT-PCR) to detect the expression of GPXs in OA patients and controls to validate our bioinformatic analysis results.

Results: Enrichment analysis showed GPXs were mainly enriched in the glutathione metabolic pathway and participate in the biological process of oxidative stress response, and further play an antioxidant role. The PPI network indicated that superoxide dismutase 1 (SOD1), superoxide dismutase 2(SOD2) and catalase (CAT) were the core proteins of this network. GPX1 was regulated by the greatest number of miRNAs. Experiments showed that the expression of GPXI was elevated in OA patients compared with controls.

**Conclusion:** GPXs play an important antioxidant role in oxidative stress response. The expression of GPX1 was elevated in peripheral blood mononuclear cells (PBMCs) of OA patients. The changes of GPXs in OA patients may regulate the level of oxidative stress, which may influence synovial lesions and chondrocyte apoptosis.

Keywords: glutathione peroxidase, biological functions, osteoarthritis

### Introduction

Osteoarthritis (OA) is a disease with joint degenerative changes as the main clinical manifestation, causing pathological changes in articular cartilage. Worldwide, more than 300 million people were reported to be affected by OA.<sup>1</sup> OA mostly occurs in the elderly, especially after the age of 50. Among them, the incidence in women is higher than that in men.<sup>2</sup> The social cost of OA may account for  $0.25\% \sim 0.50\%$  of a country's GDP.<sup>3</sup> OA has a high disability rate and seriously affects the quality of life of the elderly population, and it represents a major public health challenge.<sup>4,5</sup> OA has been reported to be associated with a number of risk factors such as age, joint injury, genetic predisposition, gender and obesity.<sup>6</sup> Studies have also revealed that OA was associated with metabolic syndrome and vascular diseases.<sup>7,8</sup> The pathological process of OA was very complex and involved multiple signaling pathways, including Wnt/β-cat-enin, TGF- $\beta$  and BMP, Indian Hedgehog, FGF, NF- $\kappa$ B, and Notch pathways.<sup>9</sup> Meanwhile, oxidative stress and synovial inflammation have been shown to be important mechanisms in the development of OA.<sup>10,11</sup>

183

Selenium is an essential micronutrient for mammals and humans, and it plays the roles of antioxidant, immune regulation and toxin antagonism in the body. The lack of selenium can lead to the occurrence of various diseases.<sup>12,13</sup> The primary biological function of selenium is mediated through selenoproteins. 25 selenoproteins have been found in the human genome so far. The glutathione peroxidase (GPX) family is one of the important components of the selenoprotein family. It is an important active oxygen free radical scavenger in the body, which can maintain the balance of oxygen metabolism in the tissue.<sup>14,15</sup> There are eight GPXs isoforms have been identified in the GPX family, namely *GPX1-GPX8*. Among them, *GPX1-GPX4* and *GPX6* were called GPXs containing selenocysteine because they used selenocysteine as their catalytic site. While *GPX5*, *GPX7* and *GPX8* used cysteine instead of selenocysteine and were called non-selenocysteine GPXs.<sup>16</sup>

Oxidative stress has been proved to be an important mechanism for the occurrence and development of OA.<sup>11</sup> Oxidative stress is a state of imbalance between reactive oxygen species (ROS) production and antioxidant defense systems. This imbalance can lead to damage to important molecules and cells, with potential consequences for the entire organism.<sup>17</sup> ROS are involved in a variety of diseases including chronic inflammation,<sup>18</sup> and even tumors.<sup>19,20</sup> In addition, studies have demonstrated that ROS are involved in inflammatory joint diseases.<sup>21,22</sup> Evidence has indicated that people with OA have higher levels of oxidative stress.<sup>23</sup> The synovial tissue of patients with arthritis has decreased levels of selenium and GPXs, decreased antioxidant capacity, and damaged chondrocyte membranes, which ultimately lead to joint degeneration.<sup>24</sup> Studies have confirmed that GPXs catalyze the reduction of H2O2 or organic hydroper-oxides to water or corresponding alcohol by utilizing glutathione (GSH) as a reducing substrate. Therefore, it can further effectively reduce the level of oxidative stress in the body.<sup>16,25</sup>

However, the association between oxidative stress in OA and the biological functions of GPXs remains unclear. The biological functions of GPXs have received more and more attention in recent years. In this study, microarray data of OA patients were used to explore GPXs expression level. Combined with the experimental study, the biological functions of GPXs and their expression in OA patients were comprehensively analyzed. We identified the core genes that GPXs mediate their biological functions, and discussed the correlation between these core genes and OA, in order to provide new ideas for the prevention and treatment of OA.

### **Materials and Methods**

### Participants and Raw Data Collection

This study explored the biological functions of five reported human selenium-containing selenoproteins GPX1, GPX2, GPX3, GPX4 and GPX6. The whole process of this study was showed in the flow chart, which was shown in Figure 1. The bioinformatic data in this study were obtained from the GEO database (https://www.ncbi.nlm.nih.gov/gds/). These data were derived from the following datasets: GSE1919, GSE32317, GSE41038, GSE46750, GSE48556, GSE55235, GSE55457. All the above 7 datasets provided microarray data of human OA group and control group. Details of the data were listed in Supplementary Table 1. In addition, 16 OA patients and 16 healthy people from Xi'an Central Hospital were included in the experimental study of this study. According to the diagnostic criteria by American College of Rheumatology, we identified 16 patients with primary OA.<sup>26</sup> They were enrolled in the study before receiving treatment after admission to the hospital. All of the patients were selected by one surgeon according to exclusion criteria, and no blinding was applied. Exclusion criteria were patients with secondary post-traumatic OA, rheumatoid arthritis (RA), infectious and endocrine-related arthropathies, acute or chronic inflammatory diseases, malignancy, renal insufficiency, diabetes, other rheumatic diseases, congenital malformations or tumors. In addition, age-, sex-, and body mass index (BMI)-matched 16 control group members were from the same region. They were recruited by orthopedic surgeons in the orthopedics outpatient clinic. The exclusion criteria for the control group were as follows: any acute or chronic inflammatory disease, any persistent joint pain, visit to a physician for joint discomfort, diabetes, malignancy, and renal insufficiency. This study was conducted in accordance with the ethical principles contained in the current version of the Declaration of Helsinki. Informed consent was signed by all participants. This study was approved by the Medical Ethics Committee of Xi'an Central Hospital (LW-2022-016).



Figure 1 A flow chart illustrating the analysis process of this study.

### GO and KEGG Pathway Enrichment Analysis of GPXs

The STRING 11.0 (https://string-db.org/) is a comprehensive and objective database that integrated all publicly available protein interaction information covering 5090 organisms and 24.6 million proteins. Its important function is to allow users to visualize gene data as interactive networks and perform gene enrichment analysis.<sup>27</sup> In this study, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using the online software STRING to further understand the biological functions of GPXs and their associated signaling pathways. GO functional enrichment analysis, which includes molecular function (MF), biological process (BP) and cell component (CC), is one of the most important bioinformatic methods for identifying the biological functions of target genes. KEGG enrichment analysis used gene expression information to identify key pathways that were associated with target genes.<sup>28,29</sup> False discovery rate (FDR)-corrected P-values less than 0.05 in GO and KEGG terms were considered significantly enriched. This study presented the top 15 GO terms and the top 20 KEGG pathways in the form of a bubble plot.

### Protein-Protein Interaction (PPI) Network Was Constructed

The confidence and other key parameters of the PPI networks of *GPX1, GPX2, GPX3, GPX4* and *GPX6* were adjusted using the online software STRING 11.0, and then the PPI network of GPXs were visualized using Cytoscape 3.8.0 software.<sup>30,31</sup> The importance of each protein in the network can be determined according to the interactions among various PPI nodes. The more interacting proteins a node has, the more important the node is in the network. Therefore, the core proteins can be identified by the PPI network of GPXs.

### Establishment of microRNAs-GPXs Interaction Network

MicroRNAs (miRNAs) plays an important role in the regulation of bodily functions. In order to determine the upstream regulatory role of microRNAs, a miRNA-GPXs regulatory network for *GPX1*, *GPX2*, *GPX3*, *GPX4* and *GPX6* was constructed in the present study. The regulatory functions of miRNAs in GPXs were analyzed by Network analyst

(<u>https://www.networkanalyst.ca/</u>)<sup>32,33</sup> and Cytoscape 3.8.0 after adjusting the filtration parameters. An interaction network was created to understand the upstream miRNA genes of GPXs.

# Establishment of Transcription Factor-GPXs Interaction Network

Transcription factor (TF) is a protein molecule with a unique structure that functions to regulate gene expression. We constructed a TF-GPXs regulatory network to examine the role of TFs in the regulation of GPXs and to identify TFs that specifically regulate GPXs by Network analyst and Cytoscape 3.8.0 in this study.

# Analysis of GPXs Expression in OA Patients

We conducted a literature search in the GEO public database PubMed (National Center for Biotechnology Information, NCBI) using the term "OA" obtained the "GSE1919" dataset submitted by Ungethuem U and Haeupl T et al (<u>https://www.ncbi.nlm.</u>nih.gov/gds/?term=GSE1919) as well as other six datasets (GSE32317, GSE41038, GSE46750, GSE48556, GSE55235 and GSE55457).<sup>34–37</sup> Inclusion criteria of the eligible datasets included: 1) Case-control study; 2) Diagnosis based on the OARSI classification criteria; 3) Specimen tissues including synovial tissue, peripheral blood, chondrocytes etc. from homo sapiens; Expression profiling data by array source data were extracted and transformed into logarithmic values as needed to ensure the reliability of subsequent data analysis. The mean and standard deviation of GPXs expression in the OA and the control group were calculated for each dataset.

We used Review Manager 5.3 for meta-analysis. A test for heterogeneity (Q test) was conducted on all 7 datasets before the meta-analysis. If  $l^2 < 50\%$  or P > 0.05 was met, then the datasets were considered homogeneous and were analyzed using the fixed effect model. On the contrary, if the datasets were not homogeneous, the cause for heterogeneity must be identified as soon as possible and the datasets were then analyzed using the random effect model. The Combined Effect Size: standard mean difference and its 95% confidence interval (95% CI.) were subsequently calculated. P < 0.05 was considered to be statistically significant.

### qRT-PCR for Validation the Results of Meta-Analysis

To validate the above results obtained by bioinformation and meta-analysis, qRT-PCR experiment was used to confirm the expression levels of main GPXs members (*GPX1* and *GPX4*), which were randomly selected from *GPX1-GPX8*. The qRT-PCR experiment was conducted based on total RNA from peripheral blood mononuclear cells (PBMCs) samples of sixteen OA patients and sixteen controls. Then the total RNA was converted into cDNA with Revert Aid RT Reverse Transcription Kit (Thermo Fisher Scientific) and qRT-PCR experiment was conducted by the platform of the ABI7500 Real-Time PCR system (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions carefully. The qRT-PCR cycling conditions were as follows: 95°C for 30s, followed by 38 cycles of 95°C for 5s and 57°C for 30s.

The primer sequences of *GPX1* and *GPX4* were as follows:

GPX1 forward, 5'-AAGGTACTACTTATCGAGAATGTG-3' and reverse, 5'-GTCAGCCTCGATGTCAATGGT CTG-3';

*GPX4* forward, 5'-ACAAGAACGGCTGCGTGGTGAA-3' and reverse, 5'- GCCACACACTTGTGGAGCTAGA-3';  $\beta$ -actin forward, 5'-ATTGCCGACAGGATGCAGA-3' and reverse, 5'-GAGTACTTGCGCTCAGGAGGA-3'.

All the above primers were synthesized by Beijing Huada Genetic Engineering Company (Beijing, China). The relative expression levels of the two genes were calculated based on the comparative cycle threshold (Ct) equation:  $2^{-\Delta\Delta Ct}$ , in this equation  $\Delta Ct = Ct$  (target gene) – Ct ( $\beta$ -ACTIN) and  $\Delta\Delta Ct = Mean \Delta Ct_{OA}$  – Mean  $\Delta Ct_{control}$ . Two sampling *t* test was selected to identify the significance of differences for expression of the target genes between OA and controls.

# Results

# GO and KEGG Pathway Enrichment Analysis of GPXs

Enrichment analysis of a series of pathways involved in GPXs is helpful to further evaluate the molecular mechanism of GPXs in diseases. The enrichment analysis results were shown in Figure 2. The GO enrichment analysis demonstrated



Figure 2 GO and KEGG pathway enrichment analysis of GPXs. (A) GO terms for GPXs enrichment analysis. The X-axis represents gene proportions, and the Y-axis represents enrichment terms. The three shapes of circle, triangle and square represent BP, CC and MF, respectively. The size of the shapes shows the level of enrichment. (B) KEGG pathway for GPXs enrichment analysis. The X-axis represents gene proportions, and the Y-axis represents enrichment terms. Circles represent the KEGG pathway. The size of the shape shows the level of enrichment.

that the GPXs were primarily involved in biological processes including response to oxidative stress, cellular response to chemical stimulus, response to chemical and metabolic process. The molecular functions of GPXs included antioxidant activity, peroxidase activity and glutathione peroxidase activity. The cellular components of GPXs included nuclear chromatin, nucleoplasm and intracellular organelle lumen (Figure 2A). The results of KEGG pathway analysis showed that most of the terms were enriched in glutathione metabolism, hippo signaling pathway, arachidonic acid metabolism, Huntington disease and amyotrophic lateral sclerosis (Figure 2B).

# PPI Network of GPXs

The PPI network was shown in Figure 3. The network constructed according to the biological functions of GPXs showed that Superoxide dismutase 1(SOD1), Superoxide dismutase 2(SOD2) and catalase (CAT) interact with five proteins in the PPI network. Deleting the above 3 nodes will destabilize the entire PPI network, so they were considered the core nodes of the PPI network.

### The Establishment of miRNAs-GPXs Interaction Network

The microRNA interaction network of GPXs was shown in Figure 4. 18 miRNAs (including hsa-mir-424, hsa-mir-509-3-5p, hsa-mir-15b, hsa-mir-103, hsa-mir-491-5p, hsa-mir-516a-5p, hsa-mir-107, hsa-mir-609 and hsa-mir-450-3p) were involved in the regulation of *GPX1*; 13 miRNAs were involved in the regulation of *GPX2* (hsa-mir-325, hsa-mir-149, hsa-mir-34c-3p, hsa-mir-760, hsa-mir-629 and hsa-mir-34b), and 9 miRNAs (including hsa-mir-608, hsa-mir-524-3p, hsa-mir-498, hsa-mir-873 and hsa-mir-525-3p) were involved in the regulation of *GPX3*, and 6 miRNAs (including hsamir-371-3p, hsa-mir-346, hsa-mir-657, has-mir-324-3p, has-mir-634 and has-mir-214) were involved in the regulation of *GPX4*. We found that miRNA-mediated regulation was more potent for *GPX1* and *GPX2*.

### Role of TFs in the Regulation of GPXs

The role of TFs in the regulation of GPXs was shown in Figure 5. 137 TFs were found to be involved in the regulation of the five GPXs. In particular, most TFs focus on the regulation of *GPX4*.

### Analysis of Expressions of GPXs in OA Patients

The results of the meta-analysis were shown in Figure 6. Given the selected datasets in which *GPX1* expression included were heterogeneous (I<sup>2</sup>=76%, *P*<0.05), the random effects model was used for the meta-analysis. The results of Meta-analysis showed that *GPX1* expression was significantly increased in the OA group than that in the healthy controls (95% CI=0.01–1.43,  $P \le 0.05$ ) (Figure 6A).



Figure 3 PPI network analysis of GPXs. Pink rhombuses represent GPXs and purple ovals represent interacting genes.



Figure 4 GPXs-miRNA interaction network. Red rhombuses represent GPXs. Navy blue ovals represent miRNA. Light blue ovals represent predicted proteins that coregulate with miRNA.

Similarly, the selected datasets including *GPX2* expression were heterogeneous ( $I^2=79\%$ , *P*<0.05), and the random effects model was used for Meta-analysis, which showed a decreasing trend of *GPX2* expression in the OA group compared with the control group (95% CI=-1.48–0.02, *P*>0.05) (Figure 6B).



Figure 5 Regulation of GPXs by TFs. Pink rhombuses represent GPXs and purple ovals represent interacting TFs.

The selected *GPX3* datasets were heterogeneous ( $I^2=56\%$ , P<0.05), and hence the random effects model was used for analysis. Meta-analysis showed that *GPX3* expression was significantly lower in the OA group than that in the control group (95% CI=-0.98--0.03,  $P \le 0.05$ ) (Figure 6C).

The selected *GPX4* and *GPX6* datasets were not heterogeneous ( $I^2=43\%$ , P>0.05;  $I^2=54\%$ , P>0.05), and fixed effects models were used for analyses. Meta-analysis showed that the results were not statistically significant. *GPX4* expression showed a trend of increase in the OA group compared with the control group (95% CI=-0.17-0.39, P>0.05) (Figure 6D). However, *GPX6* expression showed a trend of decrease in the OA group compared with the control group (95% CI=-0.17-0.39, P>0.05) (Figure 6D). However, *GPX6* expression showed a trend of decrease in the OA group compared with the control group (95% CI=-0.37-0.99, P>0.05) (Figure 6).

#### Validation by Expression Analysis of GPXs

*GPX1* and *GPX4* were selected for qRT-PCR analysis to validate the above analysis, and the analysis results were shown in Figure 7. The results showed that the expression level of *GPX1* in OA patients was significantly higher than that of the normal controls (Figure 7A, P<0.05). And the expression level of *GPX4* of OA patients was not significantly different with that in the control group (Figure 7B, P>0.05). The results were consistent with those obtained by meta-analysis.

Δ	GPX1										
~		OA			Control				Std. Mean Difference		Std. Mean Difference
_	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Random, 95% Cl
	GSE1919	10.57	0.26	5	10.27	0.32	5	11.9%	0.93 [-0.42, 2.27]		
	GSE32317	3.62	0.03	19	3.51	0.07	7	13.7%	2.44 [1.32, 3.57]		
	GSE41038	3.53	0.01	3	3.55	0.01	4	7.8%	-1.68 [-3.69, 0.32]		
	GSE46750	12.23	0.26	12	12	0.22	12	16.1%	0.92 [0.07, 1.77]		
	GSE48556	3.64	0.04	106	3.64	0.05	33	19.6%	0.00 [-0.39, 0.39]		-
	GSE55235	10.97	0.5	10	10.25	0.78	10	15.2%	1.05 [0.10, 2.00]		
	GSE55457	12.74	0.4	10	12.43	0.53	10	15.6%	0.63 [-0.27, 1.54]		+
	Total (95% CI)			165			81	100.0%	0.72 [0.01, 1.43]		<b>•</b>
	Heterogeneity: Tau <sup>2</sup> =	: 0.63; C	hi² = 2	4.84, d	f= 6 (P :	= 0.00	04); l² =	:76%		-	
	Test for overall effect:	Z = 1.98	) (P = (	0.05)						-4	Favours Control Favours OA

#### B GPX2

•															
			OA		Control				Std. Mean Difference		Std. Mean Difference				
	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Rando	m, 95% Cl			
	GSE1919	4.98	0.72	5	4.73	0.52	5	13.8%	0.36 [-0.90, 1.62]			-			
	GSE32317	5.03	0.17	19	5.76	0.23	7	12.5%	-3.78 [-5.20, -2.37]	•					
	GSE46750	5.56	0.09	12	5.6	0.08	12	17.9%	-0.45 [-1.27, 0.36]						
	GSE48556	6.56	0.08	106	6.62	0.11	33	21.3%	-0.68 [-1.08, -0.28]	-					
	GSE55235	5.75	0.7	10	6.06	0.68	10	17.2%	-0.43 [-1.32, 0.46]						
	GSE55457	6.8	0.9	10	6.84	0.87	10	17.3%	-0.04 [-0.92, 0.83]						
	Total (95% CI)			162			77	100.0%	-0.73 [-1.48, 0.02]						
	Heterogeneity: Tau <sup>2</sup> =	0.65; Cl	hi <sup>z</sup> = 2	3.67, di		-2 .	+	) 1		-1 2					
	restion overall ellect.	2 - 1.91	() – (	1.00)							Favours OA	Favours Con	trol		

#### C GPX3

		OA		C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
GSE1919	10.89	0.3	5	11.49	0.21	5	6.1%	-2.09 [-3.80, -0.38]	← →
GSE32317	3.7	0.36	19	3.74	0.04	7	14.5%	-0.12 [-0.99, 0.74]	
GSE41038	3.74	0.02	19	3.75	0.03	7	14.4%	-0.42 [-1.30, 0.45]	
GSE46750	11.12	0.56	12	10.87	0.72	12	15.5%	0.37 [-0.43, 1.18]	
GSE48556	6.63	0.1	106	6.66	0.12	33	23.5%	-0.28 [-0.68, 0.11]	
GSE55235	12.15	0.48	10	12.87	0.37	10	12.0%	-1.61 [-2.65, -0.57]	
G8E55457	13.44	0.38	10	13.81	0.64	10	13.9%	-0.67 [-1.58, 0.23]	
Total (95% CI)			181			84	100.0%	-0.50 [-0.98, -0.03]	•
Heterogeneity: Tau <sup>2</sup> =	0.21: C	hi <sup>z</sup> = 1	3.56. dt	f = 6 (P =	= 0.04)	): <b> </b> <sup>2</sup> = 56	5%		
Test for overall effect:	Z = 2.08	i (P = (	0.04)						-2 -1 U 1 2 Favours OA Favours Control

#### D GPX4

		OA		C	ontrol			Std. Mean Difference	Std. Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV	Fixed, 95%	CI	
GSE1919	9.94	0.18	5	9.96	0.37	5	5.1%	-0.06 [-1.30, 1.18]		-	-	_	
GSE32317	3.61	0.03	19	3.64	0.05	7	9.7%	-0.81 [-1.70, 0.09]					
GSE41038	7.76	0.2	3	7.88	0.24	4	3.3%	-0.45 [-1.99, 1.09]				-	
GSE46750	11.87	0.24	12	11.9	0.25	12	12.2%	-0.12 [-0.92, 0.68]					
GSE48556	10.01	0.5	106	9.87	0.41	33	51.0%	0.29 [-0.10, 0.68]			+=-		
GSE55235	10.58	0.32	10	10.24	0.25	10	8.5%	1.13 [0.17, 2.09]				•	
GSE55457	11.99	0.56	10	12.1	0.51	10	10.1%	-0.20 [-1.08, 0.68]		-			
Total (95% CI)			165			81	100.0%	0.11 [-0.17, 0.39]			•		
Heterogeneity: Chi <sup>a</sup> Test for overall effec	= 10.53, d t: Z = 0.79	#f=6( 9(P=0	-4	-2 Favou		2 Urs Control	4						
										1 4004	S OA Tavo	urs control	

#### E GPX6

		OA		C	ontrol			Std. Mean Difference		Std. Mean Difference			
Study or Subgroup	Mean SD Total			Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Random, 95% CI			
GSE1919	5.7	0.3	5	5.17	0.22	5	14.0%	1.82 [0.21, 3.43]			+		
GSE46750	5.64	0.1	12	5.64	0.09	12	33.8%	0.00 [-0.80, 0.80]		<b>_</b>			
GSE48556	6.64	0.1	106	6.63	0.08	33	52.2%	0.10 [-0.29, 0.49]					
Total (95% CI)			123			50	100.0%	0.31 [-0.37, 0.99]					
Heterogeneity: Tau² = Test for overall effect	= 0.19; CI : Z = 0.89	hi² = - I (P =	-2	-1 0 1 Favours Control Favours OA	2								

Figure 6 The results of microarray-based meta-analysis. (A) Forest plot of *GPX1* expression between OA group and control group. (B) Forest plot of *GPX2* expression between OA group and control group. (C) Forest plot of *GPX3* expression between OA group and control group. (D) Forest plot of *GPX4* expression between OA group and control group. (E) Forest plot of *GPX6* expression between OA group and control group. (E) Forest plot of *GPX6* expression between OA group and control group.



**Figure 7** Evaluating GPXs expression in OA patients using qRT-PCR. (**A**) Relative expressions of *GPX1* in OA patients and controls. (**B**) Relative expressions of *GPX4* in OA patients and controls. \*p < 0.05. **Abbreviation**: NS, Non-significant.

### Discussion

OA is a progressive degenerative joint disease. The pathological landscape of OA remains unclear until now, but it is certain that various pathologies associated with OA could make it worsen in combination, including cartilage degradation, subchondral bone sclerosis, angiogenesis and nerve innervation. Current therapies for symptomatic OA include oral drug administration, intraarticular drug injection, intravenous drug administration and surgical operations. Thus, exploring the pathogenesis of OA is important for both therapeutic approaches and bioengineering research.<sup>38,39</sup> OA is characterized by progressive articular cartilage degeneration, osteophyte formation and subchondral bone sclerosis. Its core features are degeneration and damage of articular cartilage. Cartilage degeneration in OA is due to the disruption of the dynamic balance caused by the activation of chondrocytes by multiple factors, in which the production of matrixdegrading enzymes exceeds the ability of chondrocytes to secrete matrix components.<sup>40</sup> Studies have shown that changes in the microenvironment of subchondral bone may directly or indirectly affect cartilage metabolism in patients with OA.<sup>41</sup> Oxidative stress was a well-established pathogenesis of OA. Elevated levels of ROS and oxidative stress in chondrocytes play a role in the formation of OA.<sup>11</sup> The incidence of OA patients is gradually increasing and poses a huge burden to human beings. Therefore, we explored the relationship between OA and GPXs in order to provide new ideas for etiological studies and the development of therapeutic measures.

In this present study, enrichment analysis revealed that GPXs were mainly involved in biological processes such as oxidative stress response and redox response. The molecular functions of GPXs include peroxidase activity and antioxidant activity. These findings demonstrated that GPXs play important antioxidant function in the body. ROS in the body is usually kept at a low level in cells and is crucial for maintaining cellular homeostasis and function. Oxidative stress occurs in the body when ROS production and antioxidant processes are out of balance.<sup>42</sup> There is increasing evidence that oxidative stress is tightly coupled with OA pathology.<sup>23</sup> Chondrocyte death is thought to be a major factor in the pathogenesis of OA, and oxidative stress appears to play an important role through chondrocyte apoptosis.<sup>40,43</sup> As one of the three most important families of antioxidant enzymes, GPXs usually play a key role in scavenging hydrogen peroxide (H2O2), organic peroxides and lipid peroxides.<sup>16</sup> Studies also indicated that *GPX1* can be activated in the process of cartilage formation and ROS in the cartilage microenvironment can be eliminated by *GPX1*.<sup>44</sup> Meanwhile, our study found that the expression of *GPX1* was elevated in OA patients. *GPX1* is a key enzyme involved in the redox metabolic cycle of glutathione. At the same time, it is also one of the critical free radical scavenging enzymes in the human body. It exists in the cytoplasm and mitochondria of eukaryotic cells.<sup>45</sup> We speculate that the level of oxidative

stress is elevated during the occurrence and development of OA, and the compensatory increase of *GPX1* further plays an antioxidant role.

Studies have shown that inflammation of the synovium is an emerging pathological mechanism in OA. Synoviumsynovial fluid-cartilage has been identified as the central axis of osteoarthritis pathology. A vicious circle-ROS, proinflammatory cytokines and cartilage degradation products that stimulate TLRs (immune responses) and activation of complementary system in OA.<sup>11</sup> Synovial inflammation and increased angiogenesis are associated with oxidative stress.<sup>11,46</sup> ROS and oxidative stress are elevated in patients with OA. Systemic oxidative stress induces synoviocytes and chondrocytes to produce IL-6, IL-8 and prostaglandins. In the inflammatory environment, the imbalance of synovial microvascular network and the increased energy demand of activated infiltrating immune cells and inflammatory cells lead to the decreased efficiency of synovial oxygenation, which further contributes to the hypoxic microenvironment. Hypoxia of synovial cells in a hypoxic microenvironment leads to mitochondrial damage, which in turn leads to elevated ROS levels and over-activated oxidative stress, further aggravating synovitis. The production of cytokines and growth factors by the inflamed synovium may affect the production of degrading enzymes and cartilage loss.<sup>46,47</sup> Studies have shown that the viscosity of synovial fluid is reduced and lipid peroxidation is increased in OA patients, suggesting a greater oxidative modification of synovial fluid components by ROS associated with OA.<sup>48</sup> Therefore, we speculate that there is a tendency to change the antioxidant status of synovial fluid in OA patients with increased GPXs activity. Another study showed that icariin can inhibit the sagging of synovial cells through the Xc/GPX4 axis, and further protect synovial cells. Meanwhile, it is also confirmed that the Xc/GPX4 axis is the mediator of the protective effect of icariin on synovitis.<sup>49</sup> These studies suggested that GPXs exhibit important antioxidant functions in humans and may be involved in the occurrence of certain bone diseases, which were consistent with the findings of this study.

Our study found that GPXs were involved in arachidonic acid metabolism. In patients with RA and OA, synovial tissue proliferates and hypertrophies due to the accumulation of neovascularization and inflammatory cells, including lymphoplasmacytic cells and macrophages. These cells were thought to be a key factor in articular cartilage and bone. Cytokines and metabolites of arachidonic acid play a potential role in this process. Arachidonic acid metabolites were able to inhibit cell proliferation in the inflamed synovium, thereby limiting arthritis inflammation and pannus formation.<sup>50,51</sup> The enrichment of GPXs in the arachidonic acid metabolic pathway suggested that GPXs may reduce the inflammatory response to OA treatment through the arachidonic acid pathway.

In addition, the PPI network of GPXs revealed that SOD1, SOD2, CAT and Glutathione-disulfide reductase (GSR) were important node of this network. GSR was also a key enzyme involved in the redox metabolic cycle of GSH and was a glutathione reductase. It can effectively remove excess ROS in cells.<sup>45,52</sup> Superoxide dismutase (SOD) and CAT were both intracellular and extracellular with several antioxidant defense lines.<sup>53</sup> Studies have shown that the levels of SOD, CAT, GPXs and other antioxidant enzymes in OA patients were reduced, and the role of oxidative stress in the pathogenesis of OA has been confirmed.<sup>48</sup> Collectively, the GPXs antioxidant system can regulate ROS levels by regulating related signaling pathways to maintain redox balance and the integrity of cellular components. Therefore, we speculate that antioxidant therapy will provide a promising approach for the prevention and treatment of OA caused by overexposure to ROS.

Meta-analysis of GPXs expression in OA showed that *GPX1* and *GPX3* expression were significantly different between the OA group and control group. In particular, the expression of *GPX1* was significantly increased, which was consistent with our experimental verification results. Therefore, the high expression of *GPX1* has a significant impact on the occurrence and development of OA patients. On the other hand, *GPX2, GPX4* and *GPX6* expression was not significant different between the OA group and control group. Our experiments also yielded similar results to the meta-analysis.

GPXs was a member of the antioxidant system. The decreased levels of *GPX2*, *GPX3* and *GPX6* in OA patients suggested that the body's antioxidant system capacity was reduced in the OA environment, further providing direct evidence that oxidative stress may play a key role in the occurrence of OA.<sup>54</sup> In clinical practice, doctors should pay more attention to the patients with decreased expression of *GPX2*, *GPX3* and *GPX6*. The antioxidant properties of these patients may have a downward trend, which may affect the treatment of diseases to a certain extent, and even affect the prognosis of patients. The clinical applications of the GPXs and whether they can serve early biomarkers for OA

development will be continue to be studied and validated. However, the results of this study have further expanded our understanding of the relationship between the GPXs and OA, as well as the biological functions, signaling pathways related to GPXs and their expressions in OA patients. It provided new evidence for better practice of preventing and treating OA in the future by GPXs.

There are some limitations in our present study. First, some of the results of this study were derived from bioinformatics analysis, and these results need to be further screened and verified by independent experiments. Second, the expression of GPXs in OA patients was obtained by meta-analysis. If on the basis of meta-analysis, the expressions of GPXs in OA patients were detected by qRT-PCR with large population, the results of the present study will be more comprehensive.

In future studies, our results will further be screened and validated by independent experiments. The implication of key members of GPXs in OA occurrence and development will be further explored. What's more, the expressions of GPXs in OA patients were detected by qRT-PCR with large population. Based on the above studies, evidence-based potential biomarkers that keep pace with clinical need will be developed.

### Conclusion

In conclusion, GPXs play an important antioxidant role in oxidative stress response. The expression of *GPX1* was elevated in PBMCs of OA patients. The changes in GPXs in patients with OA provided direct evidence that oxidative stress may play a key role in the development of OA. The changes of GPXs in OA patients may regulate the level of oxidative stress, which may influence synovial lesions and chondrocyte apoptosis.

# Abbreviations

GPX, Glutathione Peroxidase; OA, Osteoarthritis; GO, Gene Ontology; miRNAs, MicroRNAs; TF, Transcription factor; ROS, Reactive oxygen species; MF, molecular function; BP, Biological process; CC, Cell component; SOD1, Superoxide dismutase 1; SOD2, Superoxide dismutase 2; GSR, Glutathione-disulfide reductase; PPI, Protein-protein interaction; KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, False discovery rate; RA, rheumatoid arthritis; CAT, catalase; GSH, glutathione; CI, confidence interval; PBMCs, peripheral blood mononuclear cells.

# **Data Sharing Statement**

All data in this study were obtained from the corresponding author. The data that support the findings of this study are available in GEO datasets at <u>https://www.ncbi.nlm.nih.gov/gds/</u>. These data were derived from the following datasets: GSE1919, GSE32317, GSE41038, GSE46750, GSE48556, GSE55235, GSE55457.

### **Ethics Approval and Informed Consent**

This study was approved by the Medical Ethics Committee of Xi'an Central Hospital.

# **Consent for Publication**

All authors gave final approval to submit the manuscript for publication.

# Acknowledgments

We thank those who integrated and maintained the database that made our analysis possible. We thank the Xi'an Central Hospital.

# **Author Contributions**

Qianqian Zhao and Yongliang Tang: the writing of the original manuscript; Qianqian Zhao and Luyu Zhang: data collection; Na Sun and Qiling Liu: software and data analysis; Rongqiang Zhang: revision of the original manuscript. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing

the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

# Funding

This study was supported by Special R&D Program Project of Chinese Academy of Se-enriched Industry (2020FXZX05-01), Education Department of Shaanxi Provincial Government (19JS015) and Subject Innovation Team of Shaanxi University of Chinese Medicine (132041933).

### Disclosure

The authors report no conflicts of interest in this work.

### References

- 1. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*. 2018;392 (10159):1789–1858. doi:10.1016/s0140-6736(18)32279-7
- Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185–199. doi:10.1093/bmb/ lds038
- 3. Puig-Junoy J, Ruiz Zamora A. Socio-economic costs of osteoarthritis: a systematic review of cost-of-illness studies. *Semin Arthritis Rheum*. 2015;44(5):531–541. doi:10.1016/j.semarthrit.2014.10.012
- 4. Pritzker KP, Gay S, Jimenez SA, et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage. 2006;14(1):13-29. doi:10.1016/j.joca.2005.07.014
- 5. Hamood R, Tirosh M, Fallach N, Chodick G, Eisenberg E, Lubovsky O. Prevalence and Incidence of Osteoarthritis: a Population-Based Retrospective Cohort Study. J Clin Med. 2021;10(18):4282. doi:10.3390/jcm10184282
- 6. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. The Lancet. 2019;393(10182):1745-1759. doi:10.1016/S0140-6736(19)30417-9
- 7. Wang X, Hunter D, Xu J, Ding C. Metabolic triggered inflammation in osteoarthritis. Osteoarthritis Cartilage. 2015;23(1):22-30. doi:10.1016/j. joca.2014.10.002
- Lo K, Au M, Ni J, Wen C. Association between hypertension and osteoarthritis: a systematic review and meta-analysis of observational studies. J Orthop Translat. 2022;32:12–20. doi:10.1016/j.jot.2021.05.003
- 9. Lu K, Ma F, Yi D, Yu H, Tong L, Chen D. Molecular signaling in temporomandibular joint osteoarthritis. J Orthop Translat. 2022;32:21-27. doi:10.1016/j.jot.2021.07.001
- 10. Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017;19(1):18. doi:10.1186/s13075-017-1229-9
- 11. Kulkarni P, Martson A, Vidya R, Chitnavis S, Harsulkar A. Pathophysiological landscape of osteoarthritis. Adv Clin Chem. 2021;100:37-90. doi:10.1016/bs.acc.2020.04.002
- 12. Rayman MP. The importance of selenium to human health. The Lancet. 2000;356(9225):233-241. doi:10.1016/S0140-6736(00)02490-9
- 13. Malhotra S, Welling MN, Mantri SB, Desai K. In vitro and in vivo antioxidant, cytotoxic, and anti-chronic inflammatory arthritic effect of selenium nanoparticles. J Biomed Mater Res B Appl Biomater. 2016;104(5):993–1003. doi:10.1002/jbm.b.33448
- 14. Hariharan S, Dharmaraj S. Selenium and selenoproteins: it's role in regulation of inflammation. *Inflammopharmacology*. 2020;28(3):667–695. doi:10.1007/s10787-020-00690-x
- 15. Kryukov GV, Castellano S, Novoselov SV, et al. Characterization of mammalian selenoproteomes. *Science*. 2003;300(5624):1439–1443. doi:10.1126/science.1083516
- 16. Brigelius-Flohe R, Maiorino M. Glutathione peroxidases. Biochim Biophys Acta. 2013;1830(5):3289-3303. doi:10.1016/j.bbagen.2012.11.020
- 17. Kimball JS, Johnson JP, Carlson DA. Oxidative Stress and Osteoporosis. J Bone Joint Surg Am. 2021;103(15):1451-1461. doi:10.2106/ JBJS.20.00989
- 18. Di Virgilio F. New pathways for reactive oxygen species generation in inflammation and potential novel pharmacological targets. *Curr Pharm Des.* 2004;10(14):1647–1652. doi:10.2174/1381612043384727
- 19. Salganik RI, Albright CD, Rodgers J, et al. Dietary antioxidant depletion: enhancement of tumor apoptosis and inhibition of brain tumor growth in transgenic mice. *Carcinogenesis*. 2000;21(5):909–914. doi:10.1093/carcin/21.5.909
- 20. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. *Breast Cancer Res.* 2001;3(5):323–327. doi:10.1186/bcr315
- 21. Moulton PJ. Inflammatory joint disease: the role of cytokines, cyclooxygenases and reactive oxygen species. Br J Biomed Sci. 1996;53(4):317-324.
- 22. Gelderman KA, Hultqvist M, Olsson LM, et al. Rheumatoid arthritis: the role of reactive oxygen species in disease development and therapeutic strategies. *Antioxid Redox Signal*. 2007;9(10):1541–1567. doi:10.1089/ars.2007.1569
- 23. Marchev AS, Dimitrova PA, Burns AJ, Kostov RV, Dinkova-Kostova AT, Georgiev MI. Oxidative stress and chronic inflammation in osteoarthritis: can NRF2 counteract these partners in crime? *Ann N Y Acad Sci.* 2017;1401(1):114–135. doi:10.1111/nyas.13407
- 24. Kurz B, Jost B, Schunke M. Dietary vitamins and selenium diminish the development of mechanically induced osteoarthritis and increase the expression of antioxidative enzymes in the knee joint of STR/1N mice. *Osteoarthritis Cartilage*. 2002;10(2):119–126. doi:10.1053/joca.2001.0489
- Toppo S, Vanin S, Bosello V, Tosatto SC. Evolutionary and structural insights into the multifaceted glutathione peroxidase (Gpx) superfamily. *Antioxid Redox Signal*. 2008;10(9):1501–1514. doi:10.1089/ars.2008.2057

- 26. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. *Arthritis Rheum*. 1986;29(8):1039–1049. doi:10.1002/art.1780290816
- 27. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 2019;47(D1):D607–D613. doi:10.1093/nar/gky1131
- Chen L, Zhang YH, Wang S, Zhang Y, Huang T, Cai YD. Prediction and analysis of essential genes using the enrichments of gene ontology and KEGG pathways. *PLoS One.* 2017;12(9):e0184129. doi:10.1371/journal.pone.0184129
- Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353–D361. doi:10.1093/nar/gkw1092
- Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* 2003;13(11):2498–2504. doi:10.1101/gr.1239303
- Puig RR, Holmas S, Mironov V, Kuiper M. Network Building with the Cytoscape BioGateway App Explained in Five Use Cases. Curr Protoc Bioinformatics. 2020;72(1):e106. doi:10.1002/cpbi.106
- 32. Xia J, Benner MJ, Hancock RE. NetworkAnalyst-integrative approaches for protein-protein interaction network analysis and visual exploration. *Nucleic Acids Res.* 2014;42:W167–W174. doi:10.1093/nar/gku443
- Zhou G, Soufan O, Ewald J, Hancock REW, Basu N, Xia J. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. *Nucleic Acids Res.* 2019;47(W1):W234–W241. doi:10.1093/nar/gkz240
- 34. Wang Q, Rozelle AL, Lepus CM, et al. Identification of a central role for complement in osteoarthritis. Nat Med. 2011;17(12):1674-1679. doi:10.1038/nm.2543
- 35. Thomas GP, Duan R, Pettit AR, et al. Expression profiling in spondyloarthropathy synovial biopsies highlights changes in expression of inflammatory genes in conjunction with tissue remodelling genes. *BMC Musculoskelet Disord*. 2013;14:354. doi:10.1186/1471-2474-14-354
- 36. Lambert C, Dubuc JE, Montell E, et al. Gene expression pattern of cells from inflamed and normal areas of osteoarthritis synovial membrane. *Arthritis Rheumatol.* 2014;66(4):960–968. doi:10.1002/art.38315
- 37. Ramos YF, Bos SD, Lakenberg N, et al. Genes expressed in blood link osteoarthritis with apoptotic pathways. Ann Rheum Dis. 2014;73 (10):1844–1853. doi:10.1136/annrheumdis-2013-203405
- Xue X, Hu Y, Wang S, Chen X, Jiang Y, Su J. Fabrication of physical and chemical crosslinked hydrogels for bone tissue engineering. *Bioact Mater*. 2022;12:327–339. doi:10.1016/j.bioactmat.2021.10.029
- Zou Y, Huang B, Cao L, Deng Y, Su J. Tailored Mesoporous Inorganic Biomaterials: assembly, Functionalization, and Drug Delivery Engineering. Adv Mater. 2021;33(2):e2005215. doi:10.1002/adma.202005215
- Bolduc JA, Collins JA, Loeser RF. Reactive oxygen species, aging and articular cartilage homeostasis. Free Radic Biol Med. 2019;132:73–82. doi:10.1016/j.freeradbiomed.2018.08.038
- 41. Hu Y, Chen X, Wang S, Jing Y, Su J. Subchondral bone microenvironment in osteoarthritis and pain. *Bone Res.* 2021;9(1):20. doi:10.1038/s41413-021-00147-z
- 42. Kesarwani P, Murali AK, Al-Khami AA, Mehrotra S. Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease. *Antioxid Redox Signal*. 2013;18(12):1497–1534. doi:10.1089/ars.2011.4073
- 43. Lepetsos P, Papavassiliou AG. ROS/oxidative stress signaling in osteoarthritis. *Biochim Biophys Acta*. 2016;1862(4):576–591. doi:10.1016/j. bbadis.2016.01.003
- 44. Mohammedi K, Patente TA, Bellili-Munoz N, et al. Glutathione peroxidase-1 gene (GPX1) variants, oxidative stress and risk of kidney complications in people with type 1 diabetes. *Metabolism*. 2016;65(2):12–19. doi:10.1016/j.metabol.2015.10.004
- 45. Alanazi AM, Mostafa GA, Al-Badr AA. Glutathione. Profiles Drug Subst Excip Relat Methodol. 2015;40:43–158. doi:10.1016/bs. podrm.2015.02.001
- 46. Liu L, Luo P, Yang M, Wang J, Hou W, Xu P. The role of oxidative stress in the development of knee osteoarthritis: a comprehensive research review. Front Mol Biosci. 2022;9:1001212. doi:10.3389/fmolb.2022.1001212
- McGarry T, Biniecka M, Veale DJ, Fearon U. Hypoxia, oxidative stress and inflammation. Free Radic Biol Med. 2018;125:15–24. doi:10.1016/j. freeradbiomed.2018.03.042
- 48. Ostalowska A, Birkner E, Wiecha M, et al. Lipid peroxidation and antioxidant enzymes in synovial fluid of patients with primary and secondary osteoarthritis of the knee joint. Osteoarthritis Cartilage. 2006;14(2):139–145. doi:10.1016/j.joca.2005.08.009
- 49. Luo H, Zhang R. Icariin enhances cell survival in lipopolysaccharide-induced synoviocytes by suppressing ferroptosis via the Xc-/GPX4 axis. *Exp Ther Med.* 2021;21(1):72. doi:10.3892/etm.2020.9504
- 50. Chen Z, Bozec A, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. *Nat Rev Rheumatol*. 2019;15 (1):9–17. doi:10.1038/s41584-018-0109-2
- 51. Li Z, Ma D, Peng L, Li Y, Liao Z, Yu T. Compatibility of Achyranthes bidentata components in reducing inflammatory response through Arachidonic acid pathway for treatment of Osteoarthritis. *Bioengineered*. 2022;13(1):1746–1757. doi:10.1080/21655979.2021.2020394
- 52. Sies H. Role of metabolic H2O2 generation: redox signaling and oxidative stress. J Biol Chem. 2014;289(13):8735-8741. doi:10.1074/jbc. R113.544635
- Michiels C, Raes M, Toussaint O, Remacle J. Importance of Se-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress. Free Radic Biol Med. 1994;17(3):235–248. doi:10.1016/0891-5849(94)90079-5
- 54. Pazdzior M, Kielczykowska M, Kurzepa J, Luchowska-Kocot D, Kocot J, Musik I. The Oxidative Stress in Knee Osteoarthritis Patients. An Attempt of Evaluation of Possible Compensatory Effects Occurring in the Disease Development. *Medicina*. 2019;55(5). doi:10.3390/ medicina55050150

Journal of Inflammation Research

#### **Dove**press

Publish your work in this journal

The Journal of Inflammation Research is an international, peer-reviewed open-access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/journal-of-inflammation-research-journal